Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • World
  • Mid-East
  • Europe
  • Americas
  • Asia Pacific
  • Africa
  • Syrian Crisis
  • Islamophobia

UK becomes 1st country to approve Pfizer-BioNTech COVID-19 vaccine

by Agencies

ISTANBUL Dec 02, 2020 - 10:19 am GMT+3
A hand holds an ampoule with BNT162b2, the mRNA-based vaccine candidate against COVID-19, in Mainz, Germany, in this undated photo. (BioNTech handout via EPA)
A hand holds an ampoule with BNT162b2, the mRNA-based vaccine candidate against COVID-19, in Mainz, Germany, in this undated photo. (BioNTech handout via EPA)
by Agencies Dec 02, 2020 10:19 am
RECOMMENDED
Presidential candidate Petr Pavel meets with supporters during in the presidential elections in Cernoucek village, Czech Republic, Jan. 27, 2023. (AFP Photo)

Retired NATO general to beat billionaire ex-PM to Czech presidency

elections

Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use and said that it will be rolled out early next week.

"The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use," the government was cited by Reuters as saying.

"The vaccine will be made available across the U.K. from next week," it said.

Health Secretary Matt Hancock said the program would begin early next week. Hospitals, he said, were already ready to receive it.

"It is very good news," Hancock said, according to Reuters.

Pfizer said Britain's emergency use authorization marks a historic moment in the fight against COVID-19.

"This authorization is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the U.K.,” said CEO Albert Bourla, as cited by Reuters.

Other countries aren’t far behind: The U.S. and the European Union also are vetting the Pfizer shot along with a similar vaccine made by competitor Moderna Inc.

Pfizer said it would immediately begin shipping limited supplies to the U.K. – and has been gearing up for even wider distribution if given a similar nod by the U.S. Food and Drug Administration (FDA), a decision expected as early as next week.

"As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world," Bourla said.

But doses everywhere are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.

While the U.K. has ordered enough Pfizer vaccine for 20 million people, it’s not clear how many will arrive by year’s end, and adding to the distribution challenges is that it must be stored at ultra-cold temperatures.

Two doses three weeks apart are required for protection. First in line, the U.K. government says, are frontline health care workers and nursing home residents, followed by older adults.

British regulators also are considering another shot made by AstraZeneca and Oxford University. But Prime Minister Boris Johnson has warned, “we must first navigate a hard winter” of restrictions to try to curb the virus until there’s enough vaccine to go around.

Every country has different rules for determining when an experimental vaccine is safe and effective enough to use. Intense political pressure to be the first to roll out a rigorously scientifically tested shot colored the race in the U.S. and Britain, even as researchers pledged to cut no corners. In contrast, China and Russia have offered different vaccinations to their citizens ahead of late-stage testing.

The shots made by U.S.-based Pfizer and its German partner BioNTech were tested in tens of thousands of people. And while that study isn’t complete, early results suggest the vaccine is 95% effective at preventing mild to severe COVID-19 disease. The companies told regulators that of the first 170 infections detected in study volunteers, only eight were among people who’d received the actual vaccine and the rest had gotten a dummy shot.

“This is an extraordinarily strong protection,” Dr. Uğur Şahin, BioNTech’s CEO, recently told The Associated Press (AP).

The companies also reported no serious side effects, although vaccine recipients may experience temporary pain and flu-like reactions immediately after injections.

But experts caution that a vaccine cleared for emergency use is still experimental and the final testing must be completed. Still to be determined is whether the Pfizer-BioNTech shots protect against people spreading the coronavirus without showing symptoms. Another question is how long protection lasts.

The vaccine also has been tested in only a small number of children, none younger than 12, and there’s no information on its effects in pregnant women.

RECOMMENDED
Presidential candidate Petr Pavel meets with supporters during in the presidential elections in Cernoucek village, Czech Republic, Jan. 27, 2023. (AFP Photo)

Retired NATO general to beat billionaire ex-PM to Czech presidency

elections
  • shortlink copied
  • RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 vaccine race pfizer biontech united kingdom
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    Gulf Cooperation Council (GCC) states’ early diplomatic maneuvering occurred in the broader context of the nations’ strategic interests and should not be confused with unequivocal support for Russia. (Shutterstock Photo)

    Gulf states changing the face of Ukraine war

    gulf-states
    Leader of the far-right Danish political party Stram Kurs, Rasmus Paludan, stands outside the Turkish embassy in Stockholm, Sweden, Saturday, Jan. 21, 2023. (AP Photo)

    Far-right politician Paludan to burn Quran in Denmark

    ISLAMOPHOBIA

    7 killed in armed attack on synagogue in East Jerusalem

    ISRAEL

    US tells Türkiye, Sweden, Finland to solve issues among themselves

    TÜRKIYE-US-RELATIONS
    No Image
    Plastic "snow" coats Sri Lankan coast: An environmental disaster
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021